This is an interim version of our Electronic Legal Deposit Catalogue-eJournals and eBooks while we continue to recover from a cyber-attack.
Towards rational design of RAD51-targeting prodrugs: platinumIV–artesunate conjugates with enhanced cytotoxicity against BRCA-proficient ovarian and breast cancer cells. Issue 83 (19th September 2018)
Record Type:
Journal Article
Title:
Towards rational design of RAD51-targeting prodrugs: platinumIV–artesunate conjugates with enhanced cytotoxicity against BRCA-proficient ovarian and breast cancer cells. Issue 83 (19th September 2018)
Main Title:
Towards rational design of RAD51-targeting prodrugs: platinumIV–artesunate conjugates with enhanced cytotoxicity against BRCA-proficient ovarian and breast cancer cells
Abstract : Pt IV –Artesunate prodrugs target the homologous recombination protein RAD51 and exhibit higher cytotoxicity against BRCA-proficient ovarian and breast cancer cells than cisplatin. Abstract : Two Pt IV –artesunate anticancer prodrugs that target RAD51, a crucial protein in homologous recombination mediating the sensitivity of cancer cells to DNA-damaging agents, were designed; their cytotoxicities against BRCA-proficient ovarian and breast cancer cells are significantly higher than those of cisplatin.